Migraine Prophylaxis with Salmon Calcitonin: a Cross-over Double-blind, Placebo-controlled Study

Propranolol is an established agent in migraine prophylaxis. Uncontrolled studies have suggested an action in the acute attack. We present the first double-blind placebo controlled study of propranolol in 27 unselected patients with common (migraine without aura) and classical (migraine with aura) migraine. There were 23 pairs of headaches in the 14 patients who completed the study. No difference was found, when the data were analysed by headache pair or by patient, in severity duration and subjective assessment of efficacy between those treated in an attack with propranolol 40 mg and placebo.

Download Full-text

Effect of salmon calcitonin given by suppositories on bone mass in osteoporotic patients: A double blind placebo controlled study

Bone and Mineral ◽

10.1016/0169-6009(92)92032-l ◽

1992 ◽

Vol 17 ◽

pp. 173 ◽

Cited By ~ 2

Author(s):

G.P. Angelini ◽

S. Gonnelli ◽

R. Palmiari ◽

D. Agnusdei ◽

D. Vassellatti ◽

...

Keyword(s):

Bone Mass ◽

Salmon Calcitonin ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Prophylactic Treatment of Migraine with Bisoprolol

Cephalalgia ◽

10.1046/j.1468-2982.1997.1705596.x ◽

1997 ◽

Vol 17 (5) ◽

pp. 596-599 ◽

Cited By ~ 29

Author(s):

LLM van de Ven ◽

CL Franke ◽

PJ Koehler

Keyword(s):

Prophylactic Treatment ◽

Placebo Treatment ◽

Migraine Prophylaxis ◽

Controlled Study ◽

Duration Of Treatment ◽

Double Blind ◽

Double Blind Placebo ◽

History Of

The objective of the present study was to assess the efficacy of bisoprolol in migraine prophylaxis. A double-blind placebo-controlled study was conducted in 226 patients with migraine with or without aura, a migraine history of at least 2 years and at least 3 documented attacks during the 28 days run-in period. The duration of treatment was 12 weeks following an initial 28 days' run-in period. Patients reported the number of attacks and their severity in a diary. Treatment with bisoprolol 5 mg resulted in a significant reduction in the frequency of migraine attacks (39% vs 22%) compared to placebo treatment ( p<0.05). Treatment had no effect on the duration and severity of the attacks. Bisoprolol was well tolerated.

Download Full-text

Comparison of Propranolol LA 80 mg and Propranolol LA 160 mg in Migraine Prophylaxis: A Placebo Controlled Study

Cephalalgia ◽

10.1046/j.1468-2982.1993.1302128.x ◽

1993 ◽

Vol 13 (2) ◽

pp. 128-131 ◽

Cited By ~ 15

Author(s):

Hisham K Al-Qassab ◽

Leslie J Findley

Keyword(s):

Side Effects ◽

Migraine Prophylaxis ◽

Controlled Study ◽

Headache Frequency ◽

Double Blind ◽

Once Daily ◽

Double Blind Placebo ◽

Headache Severity ◽

Negative Effect ◽

Long Acting

Thirty patients with severe classical and common migraine participated in a double-blind placebo-con-trolled cross-over study of migraine prophylaxis with propranolol LA (long-acting) 80 mg once daily, or propranolol LA 160 mg once daily or placebo. Each treatment was given for two months. There were no significant differences between the three treatment periods in headache frequency, headache severity, nausea frequency or severity. There was a non-significant trend for reduced duration of headache with the two doses of propranolol. The possible reasons for this negative effect are discussed. The safety of propranolol and its lack of serious side effects were demonstrated.

Download Full-text